CKD Bio Corp. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
10,347
10,686
10,404
16,893
21,690
16,806
Total Accounts Receivable
28,695
30,775
30,853
31,755
28,757
31,056
Inventories
37,131
30,958
35,074
38,611
33,244
28,402
Other Current Assets
433
383
325
273
528
1,999
Total Current Assets
76,607
72,802
76,656
87,532
84,219
78,264
Net Property, Plant & Equipment
96,561
89,950
91,053
92,846
93,544
104,101
Total Investments and Advances
913
2,260
2,884
25
25
7
Intangible Assets
83
56
49
43
1,224
1,920
Other Assets
1,335
-
-
467
471
-
Total Assets
175,499
165,068
170,643
180,912
179,483
184,520
ST Debt & Current Portion LT Debt
13,723
9,979
8,337
10,865
5,907
Accounts Payable
11,600
9,688
7,888
8,421
9,735
Income Tax Payable
91
-
1,173
2,562
319
Other Current Liabilities
8,027
8,845
10,837
11,969
10,864
Total Current Liabilities
33,441
28,512
28,234
33,817
26,826
Long-Term Debt
3,453
282
226
169
113
Provision for Risks & Charges
3,448
4,125
5,079
4,210
2,623
Deferred Taxes
10,763
9,813
9,728
7,531
7,795
Other Liabilities
-
520
490
20
81
Total Liabilities
51,625
43,223
43,267
45,748
37,437
Common Equity (Total)
123,874
121,845
127,376
135,164
142,046
Total Shareholders' Equity
123,874
121,845
127,376
135,164
142,046
Total Equity
123,874
121,845
127,376
135,164
142,046
Liabilities & Shareholders' Equity
175,499
165,068
170,643
180,912
179,483

About CKD Bio

View Profile
Address
Chongkundang Building
Seoul SL 03742
Korea, Republic Of
Employees -
Website http://www.ckdbio.com
Updated 07/08/2019
CKD Bio Corp. engages in the manufacture and sale of raw material medicine. Its products include potassium clavulanate, demeclocycline, rifampicin, and acarbose. The company was founded on November 12, 2001 and is headquartered in Seoul, South Korea.